drugset / Trial / NCT00603291

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

NCT00603291

Phase 3 Completed 604 enrolled Eisai Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU), or either agent in combination with other oral hypoglycemic agents.

Timeline

Start
2007-12
Primary completion
2010-06
Completion
2010-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorcaserin Small molecule 10 mg

Indications